Scholars Central

Conference abstract

Development path for Rota vaccine

Authors: Lopa Adhikary

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Background: Rotavirus infection is one of the leading causes of death in children under five and accounts for half a million death per year in the world. Vaccination against Rotavirus is the best way to prevent severe Rotaviral diarrhea.Vaccines already available in the market are saving lives against severe gastroenteritis in the countries where children have access to them. The main objective of Rota vaccine program at Shantha is to develop and license a cost effective Rota vaccine in India as the Country of origin. The vaccine will subsequently be put up for UNICEF and other emerging countries. Methods: The vaccine development follows the classical path from identification of vaccine candidate, establishing proof of concept, pre-clinical development, feasibility of scale up, clinical development, optimizing production scale; capacity based on the market demand and finally delivers quality vaccine for the customer. Each and every step of the development follows the regulatory guideline of the product. The vaccine under development is live attenuated bovine-human reassortant covering the major serotypes distribution worldwide. Vaccine strains have been grown using vero cell as substrate. Clinical batches were manufactured, validated, tested and well characterized. Ready to use liquid formulation is used for the vaccine. The safety of the vaccine has been evaluated by conducting toxicology study in animals and Phase I safety trial in human adult and infants. The immunogenicity of the vaccine has been studied in Phase I/II safety-immunogenicity trial. Results: Virus titers for all serotypes are adequate enough to formulate at competitive COGS. The vaccine is well characterized and found to be stable, safe and immunogenic. Conclusion: The vaccine covers major serotypes worldwide and being all-in-one liquid formulation containing stabilizers and buffers, it has competitive advantage in the market. This vaccine will be the cost effective solution for preventing rotaviral diarrhea.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Vaccines & Vaccination.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Vaccines & Vaccination
  • SubjectVaccines & Immunisation
  • BylineArticles whose byline prints “Lopa Adhikary”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels